PBPK modeling of the antidepressant doxepin incorporating CYP2D6 genotype for precision pharmacotherapy #25
Annotations
1 notice
|
Journal publications table
Year|Title|URL|Source|DOI
-|-|-|-|-
2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/747">PBPK modeling of the antidepressant doxepin incorporating CYP2D6 genotype for precision pharmacotherapy</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/41758322/">https://pubmed.ncbi.nlm.nih.gov/41758322/</a>|Arch Pharm Res. 2026 Feb;49(2):278-291.|<a href="https://doi.org/10.1007/s12272-026-01600-5">10.1007/s12272-026-01600-5</a>
2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/746">Predicting Cumulative Neonatal Sodium Benzoate Exposures During Breastfeeding with Physiologically Based Pharmacokinetic Modelling</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/41758461/">https://pubmed.ncbi.nlm.nih.gov/41758461/</a>|Clin Pharmacokinet. 2026 May;65(5):665-680.|<a href="https://doi.org/10.1007/s40262-026-01624-6">10.1007/s40262-026-01624-6</a>
2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/745">Physiologically based pharmacokinetic modeling of immediate-release and extended-release formulations of doxazosin, an alpha-1 adrenergic receptor antagonist, with model simulations for patients with liver disease</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/41874609/">https://pubmed.ncbi.nlm.nih.gov/41874609/</a>|Naunyn Schmiedebergs Arch Pharmacol. 2026 Mar 24.|<a href="https://doi.org/10.1007/s00210-026-05191-2">10.1007/s00210-026-05191-2</a>
2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/744">Physiology-Based Pharmacokinetic Modeling for Prediction of Gentamicin Plasma Profile in Dogs with Renal Dysfunction</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/41900793/">https://pubmed.ncbi.nlm.nih.gov/41900793/</a>|Pharmaceutics. 2026 Feb 28;18(3):308.|<a href="https://doi.org/10.3390/pharmaceutics18030308">10.3390/pharmaceutics18030308</a>
2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/743">Physiologically Based Pharmacokinetic Model for Fluzoparib Among Patients With Renal Impairment</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/41945076/">https://pubmed.ncbi.nlm.nih.gov/41945076/</a>|Clin Ther. 2026 Jun;48(6):487-494.|<a href="https://doi.org/10.1016/j.clinthera.2026.03.013">10.1016/j.clinthera.2026.03.013</a>
2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/742">Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/42076117/">https://pubmed.ncbi.nlm.nih.gov/42076117/</a>|Pharmaceutics. 2026 Apr 10;18(4):465.|<a href="https://doi.org/10.3390/pharmaceutics18040465">10.3390/pharmaceutics18040465</a>
2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/741">Niraparib PBPK modeling to predict optimal dosage in patients with hepatic impairment</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/42199865/">https://pubmed.ncbi.nlm.nih.gov/42199865/</a>|Front Pharmacol. 2026 May 11:17:1736762.|<a href="https://doi.org/10.3389/fphar.2026.1736762">10.3389/fphar.2026.1736762</a>
2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/740">Predicting human pharmacokinetic parameters of drugs using a multi-tissue chip platform integrating liver, kidney, and skeletal muscle microphysiological systems</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/42047333/">https://pubmed.ncbi.nlm.nih.gov/42047333/</a>|Lab Chip. 2026 May 20;26(10):3054-3068.|<a href="https://doi.org/10.1039/d6lc00008h">10.1039/d6lc00008h</a>
2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/739">Advances in artificial intelligence for predictive toxicology: From QSAR and omics integration to clinical safety translation</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/42142468/">https://pubmed.ncbi.nlm.nih.gov/4214
|